Vibrating mesh nebulizers vs. less invasive surfactant administration in the treatment of preterm respiratory distress syndrome: a multicenter, open-label, exploratory, randomized clinical trial.

ABSTRACT:

Objective

Deficiency of pulmonary surfactant (PS) induces the onset of neonatal respiratory distress syndrome (RDS), which can lead to progressively worsening respiratory failure and even death. However, studies on improving lung function via the use of vibrating mesh nebulizer (VMN) technology to deliver PS to premature infants with RDS are limited.

Methods

This prospective multicenter, open-label, exploratory, randomized clinical trial, including 2 parallel groups and a 1:1 allocation, was conducted in 7 hospitals from Jan. 1, 2023, to Dec. 31, 2024. Premature infants born at less than 32 weeks of gestation and weighing less than 1500 g who presented after birth with RDS with the need for noninvasive ventilatory support as initial treatment were eligible for inclusion.

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC12577270 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature